Adlyfe Strikes Translational Medicine Partnership With Wyeth Pharmaceuticals for Alzheimer's Bioma... ( ROCKVILLE Md. Feb. 25 -- Adlyfe a pr...)

Navigation Links

Biology News Medicine News Biology Products Medicine Products Biology Definition Medicine Definition Biology Technology Medicine Technology Biology Dictionary Medicine Dictionary

HOME >> MEDICINE >> TECHNOLOGY

Adlyfe Strikes Translational Medicine Partnership With Wyeth Pharmaceuticals for Alzheimer's Biomarker Assay

Date:2/25/2009

ROCKVILLE, Md., Feb. 25 /PRNewswire-USNewswire/ -- Adlyfe, a private company developing novel biomarkers and diagnostic tests for amyloid diseases, announced today that it has signed an agreement with Wyeth Pharmaceuticals, a division of Wyeth, to develop biomarker assays designed to measure levels of beta amyloid in the human brain. The companies will develop assays for specific beta amyloid targets for use in facilitating the development of treatments for Alzheimer's disease. The multiyear agreement included an upfront payment and specific future milestone payments. Further details of the agreement were not disclosed.

Chief Executive Officer Alan S. Rudolph, Ph.D., MBA said, "This agreement is a strong statement on the potential of Adlyfe's Pronucleon(TM) technology. This partnership will enable us to move faster in developing our assay, which could serve as an important tool in assessing the efficacy of amyloid-targeted therapies."

Burrill LLC served as financial advisor to Adlyfe in this transaction.

About Alzheimer's disease

Alzheimer's disease (AD) is a neurodegenerative disease characterized by progressive cognitive deterioration together with declining activities of daily living and neuropsychiatric symptoms or behavioral changes. It is the most common type of dementia. As the disorder progresses, cognitive impairment extends to the domains of language, skilled movements, recognition, and those functions closely related to the frontal and temporal lobes of the brain. This pathological process consists principally of neuronal loss or atrophy, principally in the temporoparietal cortex but also in the frontal cortex, together with an inflammatory response to the deposition of amyloid plaques and neurofibrillary tangles. According to the NIH's National Institute on Aging, as many as 5.5 million Americans presently suffer from Alzheimer's disease.

Abou
'/>"/>

SOURCE Adlyfe Incorporated
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2
Related medicine technology :

1. Adlyfe Study on the Detection of Misfolded Proteins Published in the Journal Transfusion
2. Biotica Strikes Significant Collaboration Deal With GlaxoSmithKline
3. Queens University Chooses Xceeds Ziplex(R) System for Translational Research
4. Michael J. Fox Foundation Announces $11 Million in 2009 Funding for Translational, Pre-Clinical and Clinical Parkinsons Disease Research
5. Oncolytics Biotech Inc. Announces Start of Patient Enrolment in Translational Clinical Trial Investigating REOLYSIN(R) in Patients with Metastatic Colorectal Cancer
6. AIDS Healthcare Foundation Names Homayoon Khanlou, M.D. as its Chief of Medicine, U.S.
7. Results from Study Evaluating PROCRIT(R) in Intensive Care Unit Patients Published in New England Journal of Medicine
8. Personalized Medicine - The Genomic Revolution in Cardiac Care
9. Vaccine Study in New England Journal of Medicine Wrong in Concluding Mercury Exposures are Harmless, States SafeMinds
10. U.S. Preventive Medicine Acquires Specialty Disease Management
11. Preimplantation Genetic Diagnosis International Society Refutes American Society of Reproductive Medicine Opinion - States Preimplantation Genetic Screening is Beneficial When Performed in Experienced Centers

Post Your Comments:

(Date:5/22/2013)... -- MEDIFIRST SOLUTIONS, INC. (OTCQB: MFST) would like to ... company developments. As Medifirst continues to expand its business, ... Integrating social media into its investor relations strategy, the ... updates on Twitter. The Facebook homepage is Medifirst Solutions ... Says CEO Bruce J. Schoengood , ...

(Date:5/22/2013)... 22, 2013 Ranbaxy Laboratories Limited (hereafter, ... (hereafter, Daiichi Sankyo), announced on May 22 the ... to address past conduct under prior management ... Daiichi Sankyo continues to support Ranbaxy in its ... the past which led to the investigations by ...

(Date:5/22/2013)... Israel , May 22, 2013 Rosetta ... developer and provider of microRNA-based molecular diagnostics, announces that ... Chief Executive Officer of Rosetta Genomics, will deliver a ... place from June 3-6, 2013 in New York City. ... 4 th at 2:00 p.m. Eastern time. ...

Breaking Medicine Technology:Medifirst Solutions, Inc. Announces Update To Shareholders 2 Rosetta Genomics to Present at the Jefferies 2013 Healthcare Conference 2 Rosetta Genomics to Present at the Jefferies 2013 Healthcare Conference 3

[0] Medifirst Solutions, Inc. Announces Update To Shareholders [0] Ranbaxy Announces Improved Business Standards and Quality Assurance Initiatives [0] Rosetta Genomics to Present at the Jefferies 2013 Healthcare Conference

... 17 ULURU Inc. (NYSE Amex: ULU ) ... 2010. For the second quarter of 2010, the Company reported ... a net loss of $2.9 million, or $0.04 per share, for the ... the Company reported a net loss of $3.5 million, or $0.04 per ...

... Resources, one of the world,s leading research and advisory ... Competitive Landscape Seminar Series: Biologics and Biosimilars ... and future trends in the biologics and biosimilars markets ... on a range of industry and therapeutic-specific topics, and ...

Cached Medicine Technology:ULURU Inc. Reports Second Quarter 2010 Financial Results 2 ULURU Inc. Reports Second Quarter 2010 Financial Results 3 ULURU Inc. Reports Second Quarter 2010 Financial Results 4 ULURU Inc. Reports Second Quarter 2010 Financial Results 5 ULURU Inc. Reports Second Quarter 2010 Financial Results 6 Decision Resources' Competitive Landscape Seminar Series: Biologics and Biosimilars on September 14, 2010 Will Help Pharmaceutical Companies Understand Market Opportunities for Biologics and Biosimilars 2 Decision Resources' Competitive Landscape Seminar Series: Biologics and Biosimilars on September 14, 2010 Will Help Pharmaceutical Companies Understand Market Opportunities for Biologics and Biosimilars 3

ULURU Inc. Reports Second Quarter 2010 Financial Results Decision Resources' Competitive Landscape Seminar Series: Biologics and Biosimilars on September 14, 2010 Will Help Pharmaceutical Companies Understand Market Opportunities for Biologics and Biosimilars

(Date:5/22/2013)... researchers report that hospitals may be reaping enormous ... by preventable bloodstream infections contracted in their intensive ... reported online in the American Journal of ... ICU patient who develops an avoidable central line-associated ... to care for than a similar infection-free patient. ...

(Date:5/22/2013)... Ky. (PRWEB) May 22, 2013 ... Marathon bombings and the school shooting in Newtown, ... to children. , Emergency medical practitioners ... emergencies, and the Emergency Medical Services for Children ... for quality care for the youngest patients. It ...

(Date:5/22/2013)... FL (PRWEB) May 22, 2013 Space ... on as a sponsor for this weekend's I Talk to ... place at 8:00 am at Cocoa Riverside Park in Cocoa, ... through the I Talk to Strangers social movement. , As ... runners and walkers to participate in the event. Additionally, they ...

(Date:5/22/2013)... 2013 Pamela Isom, President and CEO ... Business Journal’s 2013 Women of Influence Award in recognition ... , The reception took place on Thursday, May 2 ... Influence is particularly humbling for the 5,000 people ICE ... success is to recognize the four to nine lives ...

(Date:5/22/2013)... Homeopathic Vibes is implementing new store hours to better ... during normal hours. On Wednesdays, they will now be open ... of our patients who work shifts that won’t allow them ... says owner and homeopathic consultant, Harminder Singh. Their normal hours, ... through Friday; weekends are by appointment only. , Out ...

Breaking Medicine News(10 mins):Health News:Hospitals profit when patients develop bloodstream infections 2 Health News:Hospitals profit when patients develop bloodstream infections 3 Health News:Hospitals profit when patients develop bloodstream infections 4 Health News:When Tragedies Impact Children – Kentucky Emergency Medical Services for Children (KYEMSC) Offers Specialized Training for Pediatric Emergency Care 2 Health News:Space Girl Organics to Sponsor May 25 Miracle Run/Walk 2 Health News:Pamela Isom, President and CEO of ICE Safety Solutions Inc. Receives 2013 Women of Influence Recognition and Award 2 Health News:Homeopathic Vibes Now Open Late on Wednesdays 2

[0] Hospitals profit when patients develop bloodstream infections [0] When Tragedies Impact Children – Kentucky Emergency Medical Services for Children (KYEMSC) Offers Specialized Training for Pediatric Emergency Care [0] Space Girl Organics to Sponsor May 25 Miracle Run/Walk [0] Pamela Isom, President and CEO of ICE Safety Solutions Inc. Receives 2013 Women of Influence Recognition and Award [0] Homeopathic Vibes Now Open Late on Wednesdays

... World Health Organization expected to make recommendation next week, ... Vaccine manufacturers and other health experts met Thursday at ... plot potential strategies to combat the swine flu virus ... infection worldwide. , The Associated Press reported ...

... In conjunction with CorVel Corporation,s (Nasdaq: CRVL ) quarterly earnings release, ... Internet on Thursday, June 4th at 11:30 am Eastern Time., Event: ... Hosted by: Dan Starck, President and CEO, ... Chairman, Date: 11:30 am ...

... OAK BROOK, Ill. May 14, 2009 In ... Barrett,s esophagus, electronic diagnosis overestimated the prevalence of the ... only 61.9 percent of patients assigned a billing diagnosis ... a manual record review. The study evaluated the accuracy ...

... country join forces to advocate for more research funding ... we continue to mark Food Allergy Awareness Week, Robert ... of the Food Allergy Initiative (FAI), announced the formation ... are to help build a strong nationwide presence for ...

... May 14 If the H1N1 pandemic flu follows the ... with more vigor in a second wave next fall. In ... unusual rapidity, resulting in 3 explosive pandemic waves within a ... for the Prudent Use of Antibiotics and Microbiology Lab Director ...

... of life over 8 years of follow-up, study finds, ... (ICDs) extend heart patients, lives even eight years after ... be presented Thursday at the Heart Rhythm Society annual ... ICD therapy, sustained for over eight years, does in ...

Health Experts Plot Strategy for Swine Flu Vaccine CorVel Announces Fiscal Year Earnings Release Webcast Study examines reliability of clinical and pathological diagnoses of Barrett's esophagus Robert F. Kennedy, Jr. Announces New Food Allergy Initiative Advocacy Steering Committee H1N1 Pandemic Precautions for Front Line Workers Implanted Defibrillators Boost Long-Term Survival

... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...

... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...

... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...

Medicine Products:

Doxepin, Urine Drinox, Serum Dramamine, Urine Doxycycline, Antimicrobial (Serum or Body Fluid) Level, BA